Insider Transactions in Q1 2026 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,928
-0.51%
|
$124,488
$21.77 P/Share
|
|
Jan 22
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
3,371
-4.12%
|
$70,791
$21.77 P/Share
|
|
Jan 22
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,064
-3.98%
|
$43,344
$21.77 P/Share
|
|
Jan 22
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,797
-3.13%
|
$58,737
$21.77 P/Share
|
|
Jan 22
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
7,832
-8.13%
|
$164,472
$21.77 P/Share
|
|
Jan 22
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,287
-9.87%
|
$216,027
$21.77 P/Share
|
|
Jan 22
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,725
-9.8%
|
$162,225
$21.77 P/Share
|
|
Jan 22
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,192
-8.68%
|
$571,032
$21.77 P/Share
|
|
Jan 20
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
909
-0.08%
|
$17,271
$19.79 P/Share
|
|
Jan 20
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,334
-1.61%
|
$25,346
$19.79 P/Share
|
|
Jan 20
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
726
-1.38%
|
$13,794
$19.79 P/Share
|
|
Jan 20
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,882
-2.06%
|
$35,758
$19.79 P/Share
|
|
Jan 20
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,892
-2.7%
|
$54,948
$19.79 P/Share
|
|
Jan 20
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,203
-2.72%
|
$41,857
$19.79 P/Share
|
|
Jan 20
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,182
-2.55%
|
$155,458
$19.79 P/Share
|
|
Jan 20
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
2,475
-2.5%
|
$47,025
$19.79 P/Share
|
|
Jan 13
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,618
-3.13%
|
$57,596
$22.19 P/Share
|
|
Jan 13
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,186
-3.07%
|
$224,092
$22.19 P/Share
|
|
Jan 13
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,277
-0.2%
|
$50,094
$22.19 P/Share
|
|
Jan 13
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,780
-2.1%
|
$39,160
$22.19 P/Share
|
|
Jan 13
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
873
-1.63%
|
$19,206
$22.19 P/Share
|
|
Jan 13
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,780
-5.52%
|
$127,160
$22.19 P/Share
|
|
Jan 13
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,856
-3.48%
|
$84,832
$22.19 P/Share
|
|
Jan 07
2026
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
888
+0.84%
|
$12,432
$14.95 P/Share
|
|
Jan 05
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,020
-3.21%
|
$75,500
$25.53 P/Share
|
|
Jan 01
2026
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+2.03%
|
-
|
|
Jan 01
2026
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+31.83%
|
-
|
|
Jan 01
2026
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+20.61%
|
-
|
|
Jan 01
2026
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+23.67%
|
-
|
|
Jan 01
2026
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+23.67%
|
-
|
|
Jan 01
2026
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+4.7%
|
-
|
|
Jan 01
2026
|
Craig A Wheeler Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+24.57%
|
-
|